Seat­tle biotech found­ed by for­mer Seagen lead­ers nabs $112M for three clin­i­cal-stage AD­Cs

Pro­found­Bio will use a larg­er-than-planned Se­ries B to fi­nance three clin­i­cal-stage an­ti­body-drug con­ju­gates, in­clud­ing tak­ing its lead com­pound in­to a piv­otal study and help­ing ad­vance …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER